Tryptophan-Associated Eosinophilic Connective-Tissue Disease: A New Clinical Entity?

Daniel J. Clauw, David J. Nashel, Andrew Umhau, Paul Katz

Research output: Contribution to journalArticle

69 Scopus citations

Abstract

Seven patients who developed a syndrome of eosinophilia, connective-tissue disease, and cutaneous abnormalities while ingesting tryptophan were examined. Other clinical manifestations commonly seen were pulmonary symptoms, fever, lymphadenopathy, and the development of myopathy. Laboratory features included mild elevations of aldolase and lactate dehydrogenase levels, with essentially normal creatine kinase levels, erythrocyte sedimentation rates, and C-reactive protein levels. Biopsy findings included features of scleroderma, small-vessel vasculitis, fasciitis, and myopathy. Discontinuation of tryptophan administration and implementation of corticosteroid therapy were of some benefit in relieving the intense myalgias and cutaneous findings that developed. Although temporally related to tryptophan ingestion, it is unclear whether this substance, a metabolite, or a contaminant were causal. We speculate that the pathogenesis of this syndrome may relate to abnormalities in tryptophan metabolism.

Original languageEnglish (US)
Pages (from-to)1502-1506
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume263
Issue number11
DOIs
StatePublished - Mar 16 1990

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Tryptophan-Associated Eosinophilic Connective-Tissue Disease: A New Clinical Entity?'. Together they form a unique fingerprint.

  • Cite this